We are live on ! Find out more
EW icon

Edwards Lifesciences

556 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 193 increasing their positions, 182 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

12% more funds holding

Funds holding: 496556 (+60)

6% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 182

5% less capital invested

Capital invested by funds: $12.4B → $11.7B (-$651M)

7.78% less ownership

Funds ownership: 523.44%515.66% (-7.8%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
556
Holders Change
+60
Holders Change %
+12.1%
% of All Funds
14.83%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
193
Reduced
182
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M
Name Holding Trade Value Shares
Change
Change in
Stake
LG
451
LaFleur & Godfrey
Michigan
$255K
SLG
452
Stanley-Laman Group
Pennsylvania
$255K
Marshall Wace
453
Marshall Wace
United Kingdom
$254K -$136K -6,774 -36%
SB
454
Suntrust Banks
Georgia
$254K -$75.5K -3,756 -24%
AI
455
Atria Investments
North Carolina
$251K -$30.4K -1,512 -11%
AIP
456
Ameritas Investment Partners
Nebraska
$248K +$235K +11,676 New
ZDA
457
Zweig-DiMenna Associates
New York
$242K +$229K +11,400 New
BPC
458
Banque Pictet & Cie
Switzerland
$236K -$18.1K -900 -8%
FA
459
FDx Advisors
Illinois
$235K +$223K +11,088 New
AIM
460
Aspen Investment Management
Michigan
$234K +$221K +11,010 New
BGIM
461
Boussard & Gavaudan Investment Management
United Kingdom
$233K -$124K -6,156 -36%
SFPIA
462
Stevens First Principles Investment Advisors
California
$231K -$13.3K -660 -6%
OA
463
OFI Advisors
Pennsylvania
$229K +$21.2K +1,056 +11%
MYLI
464
Meiji Yasuda Life Insurance
Japan
$226K -$362K -18,000 -63%
SAM
465
SignalPoint Asset Management
Missouri
$225K +$213K +10,578 New
SKK
466
Shepherd Kaplan Krochuk
Massachusetts
$223K -$177K -8,820 -46%
OAM
467
Orinda Asset Management
California
$221K +$209K +10,404 New
EOJOAM
468
E. Ohman J:or Asset Management
Sweden
$220K
HFS
469
HL Financial Services
Kentucky
$217K +$205K +10,200 New
GLRA
470
Gerald L. Ray & Associates
Texas
$217K +$205K +10,206 New
1SB
471
1ST Source Bank
Indiana
$214K +$203K +10,080 New
Verition Fund Management
472
Verition Fund Management
Connecticut
$208K -$294K -14,646 -60%
QSS
473
Quantitative Systematic Strategies
Florida
$204K +$192K +9,540 New
AP
474
Advisor Partners
California
$204K +$193K +9,594 New
ZIG
475
Zuckerman Investment Group
Illinois
$204K +$193K +9,600 New

EW Hedge Fund Activity: Q4 2014 in Review

556 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — down 5.3% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 193 added to existing stakes and 182 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 556 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 496 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, down 5.3% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.